CA3051989A1 - Dosing schedule of a wnt inhibitor and an anti-pd-1 antibody molecule in combination - Google Patents

Dosing schedule of a wnt inhibitor and an anti-pd-1 antibody molecule in combination Download PDF

Info

Publication number
CA3051989A1
CA3051989A1 CA3051989A CA3051989A CA3051989A1 CA 3051989 A1 CA3051989 A1 CA 3051989A1 CA 3051989 A CA3051989 A CA 3051989A CA 3051989 A CA3051989 A CA 3051989A CA 3051989 A1 CA3051989 A1 CA 3051989A1
Authority
CA
Canada
Prior art keywords
treatment
day
administered
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3051989A
Other languages
English (en)
French (fr)
Inventor
Jason Russell DOBSON
Susan MOODY
Margaret Elise MCLAUGHLIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CA3051989A1 publication Critical patent/CA3051989A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CA3051989A 2017-02-14 2018-02-12 Dosing schedule of a wnt inhibitor and an anti-pd-1 antibody molecule in combination Pending CA3051989A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762458640P 2017-02-14 2017-02-14
US62/458,640 2017-02-14
US201862616682P 2018-01-12 2018-01-12
US62/616,682 2018-01-12
PCT/IB2018/050846 WO2018150312A1 (en) 2017-02-14 2018-02-12 Dosing schedule of a wnt inhibitor and an anti-pd-1 antibody molecule in combination

Publications (1)

Publication Number Publication Date
CA3051989A1 true CA3051989A1 (en) 2018-08-23

Family

ID=61526841

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3051989A Pending CA3051989A1 (en) 2017-02-14 2018-02-12 Dosing schedule of a wnt inhibitor and an anti-pd-1 antibody molecule in combination

Country Status (12)

Country Link
US (2) US11406633B2 (https=)
EP (1) EP3582811B1 (https=)
JP (3) JP2020506159A (https=)
KR (2) KR20240007717A (https=)
CN (2) CN110267682A (https=)
AU (1) AU2018221557C1 (https=)
CA (1) CA3051989A1 (https=)
IL (1) IL268341B2 (https=)
MX (1) MX2019009630A (https=)
RU (1) RU2767533C2 (https=)
TW (1) TWI771372B (https=)
WO (1) WO2018150312A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
ES2771926T3 (es) 2014-09-13 2020-07-07 Novartis Ag Terapias de combinación
WO2017106656A1 (en) * 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
US20210395351A1 (en) * 2018-09-27 2021-12-23 Musc Foundation For Research Development Pharmaceutical combination for the treatment of cancer
WO2020236078A1 (en) * 2019-05-22 2020-11-26 Agency For Science, Technology And Research Pharmaceutical combination
CN113134090B (zh) * 2021-03-26 2022-05-17 武汉大学中南医院 一种抗肿瘤药物组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA103918C2 (en) 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
US20160303137A1 (en) * 2015-04-20 2016-10-20 Indiana University Research And Technology Corporation Dual pi3k and wnt pathway inhibition as a treatment for cancer
CN104767366A (zh) * 2015-04-21 2015-07-08 永济新时速电机电器有限责任公司 辅助变流器和车辆
EP3302467A4 (en) * 2015-05-31 2019-01-02 Curegenix Corporation Combination compositions for immunotherapy

Also Published As

Publication number Publication date
IL268341A (en) 2019-09-26
JP2022174157A (ja) 2022-11-22
KR20240007717A (ko) 2024-01-16
IL268341B2 (en) 2023-06-01
JP2024133495A (ja) 2024-10-02
US20190365746A1 (en) 2019-12-05
AU2018221557C1 (en) 2021-10-14
CN110267682A (zh) 2019-09-20
AU2018221557A1 (en) 2019-08-15
WO2018150312A1 (en) 2018-08-23
US11406633B2 (en) 2022-08-09
RU2767533C2 (ru) 2022-03-17
RU2019128843A3 (https=) 2021-05-17
KR20190112801A (ko) 2019-10-07
RU2019128843A (ru) 2021-03-16
TW201836610A (zh) 2018-10-16
MX2019009630A (es) 2019-11-08
EP3582811A1 (en) 2019-12-25
JP2020506159A (ja) 2020-02-27
EP3582811B1 (en) 2024-07-10
CN117752784A (zh) 2024-03-26
TWI771372B (zh) 2022-07-21
US20230063366A1 (en) 2023-03-02
AU2018221557B2 (en) 2021-03-11

Similar Documents

Publication Publication Date Title
US20230063366A1 (en) Dosing schedule of a Wnt inhibitor and an anti-PD-1 antibody molecule in combination
US11001628B2 (en) Combined use of anti PD-1 and anti M-CSF antibodies in the treatment of cancer
US20190175609A1 (en) Therapeutic uses of a c-raf inhibitor
US20180177872A1 (en) Combination of PD-1 antagonist with an EGFR inhibitor
EP3380523A1 (en) Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
CN113045655A (zh) 抗ox40抗体及其用途
US20220306737A1 (en) Use of high-affinity, ligand-blocking, humanized anti-t-cell immunoglobulin domain and mucin domain-3 (tim-3) igg4 antibody for the treatment of myelofibrosis
CA3221035A1 (en) Transforming growth factor-beta ligand traps for the treatment of disease
US20250215087A1 (en) Combination therapy of kras inhibitor and treg depleting agent
BR112019017696A2 (pt) programa de dosagem para uma combinação de ceritinib e uma molécula de anticorpo anti-pd-1
AU2021260982B2 (en) Dosing regimen for treating a disease modulated by CSF-1R
RU2835316C1 (ru) Режим введения доз для лечения заболевания, модулируемого csf-1r
HK40011167B (en) Dosing schedule of a wnt inhibitor and an anti-pd-1 antibody molecule in combination
HK40011167A (en) Dosing schedule of a wnt inhibitor and an anti-pd-1 antibody molecule in combination
HK40053431A (en) Anti-ox40 antibody and use thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220922

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241206

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241206

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241206

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250304

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20250704